Category: Pharmacy Industry

Posted on

Drug companies brace for chairman Bernie

Drug companies brace for chairman Bernie

Sen. Bernie Sanders (I-Vt.) speaks to associates of the push outside the house the White Dwelling on Jan. 25. Photo: Alex Wong/Getty Pictures

Sen. Bernie Sanders has very long produced no key that he thinks drug organizations and overall health insurers are ripping off People. But now he’s chairman of the Senate health committee.

Why it issues: Sanders has signaled an early concentrate of the committee’s operate will be drug rates, and manufacturers are bracing for some contentious hearings.

  • “I have no doubt there will be challenging hearings with individuals from business remaining compelled to testify, subpoenaed to testify, and many others.,” a pharmaceutical sector source explained. “And I imagine that’s going to be a authentic problem.”

What they’re saying: Sanders advised Axios in a brief hallway interview past week that he does approach to have hearings in the Overall health, Instruction, Labor and Pensions (Support) Committee on drug price ranges.

  • Asked specifically if that will involve calling drug firm executives to testify, Sanders reported: “We’re working on a tactic suitable now that will be incredibly intense.”
  • Sanders has presently set the tone for his chairmanship with a Fox News op-ed saying “greedy pharma rips off Americans.” In a brief video clip he posted on Twitter, Sanders previewed the committee’s agenda, including how it would “get on the greed of the pharmaceutical market.”
  • Sanders allies say it is very little key that he wants to press pharmaceutical executives. “I believe pretty around the to start with purchase of enterprise for Bernie Sanders at Assistance is calling these firms to account,” reported Alex Lawson, govt director of the progressive team Social Protection Is effective.
  • Lawson said he expects Sanders to mail letters to drug organizations with inquiries in advance of calling hearings.
  • “It does not get looking through tea leaves to believe that Sanders will want to do that,” Louisiana Sen. Bill Cassidy, the top rated Republican on Enable, explained of drug organization hearings. “If he calls them in, I have queries,” he additional.

Involving the lines: The vital upside for sector is that with a divided Congress, Sanders has basically no capability to get his most sweeping suggestions signed into legislation at the moment. What he will have is the use of the bully pulpit and the general public relations fight.

  • “We’re looking at firms intensify their proactive instruction and advocacy initiatives, whilst also planning to deal with refreshing attacks from the senator,” reported a specialist who will work with pharmaceutical providers.
  • The specialist added that there is hope consideration can shift to other players in the drug offer chain, starting off with pharmacy gain managers, or PBMs, who negotiate drug rates on behalf of health options and have been the target of more finger-pointing about what sufferers in fact pay out at the pharmacy counter.
  • Lori Reilly, main running officer at the Pharmaceutical Study and Producers of The us, explained they are “getting ready for something and almost everything” when questioned about Sanders as chairman.
  • She reported they had not listened to right from him about hearings, but “my assumption is he will be possessing hearings on that, and our firms have testified right before and we’ve testified just before, so I wouldn’t be amazed if that transpires.”

  • PhRMA spokesman Brian Newell mentioned in a statement that “we are not able to dismiss the genuine motorists of overall health care investing or middlemen who are shifting charges onto folks at the pharmacy.”

Hold in mind: Democrats last year fulfilled a lengthy-held target by passing drug pricing provisions in the Inflation Reduction Act that for the initial time gave Medicare the power to negotiate the charges of some medicine that have been on the industry for various yrs but do not have competitiveness from generics.

Even though Sanders has set his early focus on drug companies, the Medicare for All proponent and two-time presidential applicant is unquestionably no fan of overall health insurers possibly. But a single wellbeing insurance plan market executive said they hope to get the job done with him on drug pricing — and placing heat on brands.

  • “Senator Sanders undoubtedly has his position of look at,” David Merritt, a senior vice president at the Blue Cross Blue Protect Association, informed reporters final week. “I do feel we can come across some typical floor on the require to reform the prescription drug business.”

The base line: Sanders is receiving prepared for a combat.

  • “Even so fearful they are, they are not worried more than enough,” Lawson explained of the health and fitness treatment field. “For the reason that that’s the vitality that Bernie Sanders, from my opinion from speaking with Help, is bringing to this.”

A variation of this story was released very first on Axios Professional. Get information like this by subscribing. Use code Coverage100 which gives you $100 off.

Posted on

Neighbourly Appoints Pharmacy Industry Veteran Skip Bourdo as CEO

Neighbourly Appoints Pharmacy Industry Veteran Skip Bourdo as CEO

Chris Gardner to stage into Strategic Advisor purpose soon after 5 many years of excellent leadership

TORONTO, Jan. 24, 2023 /CNW/ – Neighbourly Pharmacy Inc. (TSX: NBLY) (“Neighbourly” or the “Firm“), announces today the appointment of Skip Bourdo as Chief Government Officer.  Chris Gardner has decided to move down as CEO and will carry on to support the Company in a Strategic Advisor part.

Neighbourly Pharmacy Logo (CNW Group/Neighbourly Pharmacy Inc.)

Neighbourly Pharmacy Logo (CNW Group/Neighbourly Pharmacy Inc.)

Skip Bourdo is an accomplished pharmacy and healthcare government with 30 several years of marketplace expertise. Mr. Bourdo experienced a effective 27-year vocation at Walgreens, just one of North America’s greatest pharmacy chains, starting off as a cashier, then keep supervisor, and developing in positions of at any time-rising obligation, which include integration and enterprise transformation roles, and culminating as Group Vice President, Pharmacy and Retail Discipline Operations for Walgreens’ Western operations, exactly where he oversaw a network masking 4,700 retail, wellness procedure and specialty pharmacy areas, generating around $46 billion in income, and utilizing in excess of 120,000 group users in 29 states, Puerto Rico and the U.S. Virgin Islands, serving virtually 4 million consumers and patients just about every working day.

A lot more recently, Mr. Bourdo was Main Operating Officer of Athletico, a fast expanding, leading supplier of orthopedic rehabilitation companies across the United States. In the course of his tenure at Athletico, Mr. Bourdo was liable for bringing operational excellence, composition, and scale abilities to Athletico’s clinic operations, which nearly doubled their retail footprint to 950+ places above the system of two a long time.

“We are thrilled to welcome Skip Bourdo to Neighbourly,” stated Stuart M. Elman, Chair of Neighbourly’s Board of Directors. “Skip is a seasoned pharmacy and healthcare chief with a wealth of operational and M&A practical experience.  Skip’s outstanding observe file of driving development, profitability and operational excellence will be significant as Neighbourly carries on on its expansion trajectory,” concluded Mr. Elman.

Mr. Bourdo stated, “I am honoured and amazingly psyched to get on the CEO position and direct Neighbourly by its future section of expansion. I search ahead to continuing Neighbourly’s concentrate on growing its network of unbiased pharmacies, when driving the wellbeing and profitability of the small business and continuing to guidance the well being needs of the communities we serve every working day across Canada.”

The appointment of Skip Bourdo follows a demanding lookup method, which thought of substantial excellent candidates from Canada and the Usa.

Chris Gardner carries on to be fully commited to the success and development of the Corporation and will continue to be with Neighbourly as a Strategic Advisor, supporting Mr. Bourdo and the Board of Administrators about the future twelve months, which include continuing to execute on the Firm’s sturdy acquisition pipeline. Mr. Gardner joined Neighbourly in 2017 and turned CEO in February 2019 leading the Firm’s quick development – driving a practically 5-fold maximize from 61 areas to 284 areas coastline to coast, as well as its general public offering in 2021.

“On behalf of myself and the Board, I’d like to thank Chris for his management and important contribution to Neighbourly’s accomplishment in excess of the previous 5 years. Chris joined the Corporation all through the early phases of the organization’s historical past and led Neighbourly by means of a period of exponential advancement. Below Chris’ management, the Enterprise was acknowledged as the Swiftest Increasing Business in Canada in 2020 by the World and Mail and one particular of Canada’s Most effective Managed Providers by Deloitte for the past 2 consecutive years. We are grateful to depend on Chris’ ongoing help as a Strategic Advisor,” mentioned Mr. Elman.

Chris Gardner mentioned, “I am very happy of Neighbourly’s success about the earlier 5 many years, and I glimpse forward to supporting Skip and the Board of Administrators by means of this up coming phase of our development.” Chris Gardner added, “I am enthusiastic to welcome a chief of Skip’s caliber and encounter to Neighbourly and glance ahead to supporting him as he leads this excellent corporation to new heights.”

About Neighbourly Pharmacy Inc.

Neighbourly is Canada’s greatest and fastest growing network of group pharmacies. United by their client 1st emphasis and their part as essential and trustworthy health care hubs within their communities, Neighbourly’s pharmacies try to give accessible healthcare with a personal touch. Considering the fact that 2015, Neighbourly has expanded its diversified national footprint to include things like 284 destinations, reinforcing the Firm’s name as the industry’s acquirer of option.

Supply Neighbourly Pharmacy Inc.

Cision

Cision

View unique written content to obtain multimedia: http://www.newswire.ca/en/releases/archive/January2023/24/c0902.html

Posted on

Drug companies brace for Bernie Sanders

Drug companies brace for Bernie Sanders

Bernie Sanders has long manufactured no top secret that he thinks drug firms and wellness insurers are ripping off Us residents. But now he’s a chairman.

Why it matters: Sanders has signaled an early emphasis on drug prices in individual, and drug businesses are bracing for some contentious hearings.

  • “I have no question there will be rough hearings with men and women from industry getting compelled to testify, subpoenaed to testify, and so forth.,” a pharmaceutical field resource claimed. “And I feel that’s heading to be a actual obstacle.”

What they’re indicating: Sanders informed Axios in a quick hallway job interview this 7 days that he does strategy to have Support Committee hearings on drug rates.

  • Asked especially if that will contain calling drug corporation executives to testify, Sanders mentioned: “We are working on a technique correct now that will be incredibly intense.”
  • Sanders has currently set the tone for his chairmanship with a Fox Information op-ed indicating “greedy pharma rips off People.”
  • Sanders allies say it is small mystery that he wants to push pharmaceutical executives. “I believe extremely near the to start with purchase of business enterprise for Bernie Sanders at Help is calling these organizations to account,” stated Alex Lawson, govt director of the progressive group Social Security Performs.
  • Lawson reported he expects Sanders to mail letters to drug companies with issues before calling hearings.
  • “It would not choose looking through tea leaves to imagine that Sanders will want to do that,” Sen. Monthly bill Cassidy, the top Republican on Enable, said of drug firm hearings. “If he phone calls them in, I have concerns,” he added.

Involving the strains: The vital upside for sector is that with a divided Congress, Sanders has mainly no capacity to get his most sweeping tips signed into legislation at the minute. What he will have is the use of the bully pulpit and the general public relations struggle.

  • “We’re looking at businesses intensify their proactive instruction and advocacy attempts, though also planning to deal with refreshing attacks from the senator,” reported a marketing consultant who functions with pharmaceutical firms.
  • The guide additional that there is hope that other areas of the source chain, like PBMs, acquire some of the hits way too, specified their purpose in what clients truly pay back at the pharmacy counter.
  • Lori Reilly, main working officer at PhRMA, claimed they are “preparing for everything and every thing” when questioned about Sanders as chairman.

  • She explained they experienced not heard straight from him about hearings, but “my assumption is he will be getting hearings on that, and our businesses have testified prior to and we have testified just before, so I wouldn’t be surprised if that transpires.”
  • PhRMA spokesman Brian Newell said in a statement that “we can not ignore the authentic motorists of overall health treatment paying out or middlemen who are shifting charges on to people today at the pharmacy.”

When Sanders has place his early target on drug firms, the Medicare for All proponent is definitely no fan of overall health insurers both. But 1 wellbeing insurance policies sector government claimed they hope to perform with him on a shared foe: significant drug prices.

  • “Sen. Sanders undoubtedly has his point of see,” David Merritt, a senior vice president at the Blue Cross Blue Shield Association, explained to reporters this week. “I do believe we can discover some widespread ground on the want to reform the prescription drug marketplace.”

The base line: Sanders is receiving completely ready for a battle.

  • “However terrified they are, they’re not terrified ample,” Lawson claimed of the overall health care marketplace. “Because which is the electrical power that Bernie Sanders, from my feeling from speaking with Enable, is bringing to this.”
Posted on

With RxPass, Amazon is looking to grow its pharmacy business

With RxPass, Amazon is looking to grow its pharmacy business

Amazon’s enlargement into health treatment will come as the e-commerce large faces a person of its most challenging durations in its heritage. Past yr, the firm witnessed a slowdown in its core e-commerce business enterprise, and it has also started a massive cost-slicing overview, indicating the business is getting ready for a further more slowdown.

Industry experts advised Modern-day Retail this new subscription drug presenting alerts an acknowledgment of Amazon’s evolving purchaser foundation. Just one qualified explained to Contemporary Retail that Amazon is hoping to develop its wallet share by including this new benefit for Key customers. And a lot more broadly, Amazon’s providing also signifies a bigger change to convey down drug rates forward of the rollout of the Inflation Reduction Act in 2025. The two governing administration subsidies and individual out-of-pocket fees are anticipated to be significantly decreased as a end result of the monthly bill.

“I believe portion of it is recognition of what is happening demographically in this region. We’re all having more mature and sicker. And if you’re Amazon and you want to stay dominant for the upcoming 20 several years and not be disrupted, then you can not afford to pay for any longer to overlook well being care,” Christina Farr, a overall health technological innovation investor at Omers Ventures informed Contemporary Retail.

“There’s this stress on the pharmaceutical and drug marketplace to deliver drug costs down. And, as a result, you see individuals like Amazon, Walmart, CVS, all of the stores that have pharmacy property, commencing to set choices in the market. That puts pressure on bringing some of individuals drug prices down for customers,” claimed Kate McCarthy, vice president of Gartner’s wellness treatment and daily life science business study workforce.

Amazon first acquired into the prescription area in 2018, when the company ordered on the internet pharmacy PillPack. Amazon inevitably released its individual pharmacy company in 2020 to attract consumers made use of to viewing the community pharmacy by leveraging the ease of its Primary transport services. Shoppers use Amazon’s support to manage prescriptions and find payment procedures. Amazon also manufactured its prescription medication purchasing and success provider out there on mobile equipment.

“They [Amazon] have not experienced as much volume in the pharmacy enterprise as they would like. So, putting some thing significantly extra competitive in the current market could enable them to get additional of their faithful consumer foundation that presently has Prime to commence employing their pharmacy provider,” mentioned McCarthy.

Farr, meanwhile, explained that the launch of RxPass — and Amazon’s efforts in the pharmacy room far more broadly — need to all be seen as component of an built-in approach to grow to be the “digital entrance doorway for overall health care.”

Over the yrs, Amazon has been doubling down on its foray into health and fitness care in other ways. In July of last 12 months, Amazon announced it was obtaining Just one Healthcare, an operator of major-treatment clinics, in a offer truly worth $3.9 billion. In 2019, the corporation launched Amazon Treatment, a telemedicine and most important care provider. At first, it was only for Amazon workforce. But Amazon experimented with to supply it to other company consumers. In the end Amazon terminated its Care solutions unit at the finish of 2022, simply because it was not a sustainable, lengthy-phrase resolution for its company prospects.

Independently, last year, the organization also released Amazon Clinic, a information-primarily based telehealth company that offers distant remedy for allergy symptoms and heartburn.

“I assume the motive pharmacy was the space that vendors entered into initial, no matter whether it was CVS, Ceremony Assist, or just about each individual other retailer, was simply because it is a source chain business enterprise. Stores already control source chain as component of what they do. And so it is the closest parallel to their business. And after they sense like they have a sense of the pharmacy small business, and once they’ve figured out how to securely handle individual data, well, then relocating to factors like immediate care and so on,” discussed McCarthy.

Farr extra that portion of the reason why Amazon moved into the health care sector was to tackle the modifying requirements of its buyers, notably with millennials who use its Key assistance. “Millennials are acquiring more mature also — we’re shifting into our 30s and 40s, and increasingly getting drugs. So this, to me, is a additional of a recognition of that, the desires of the main customer foundation and adapting to them,” included Farr.

McCarthy added that Amazon’s new plan is a “substantial effort” to transform the financial forces in prescription shipping at a time when there is an inflow of new choices from other rivals in the industry in progress of the 2025 inflation Reduction Act measures.

For case in point, McCarthy pointed out that billionaire Mark Cuban’s latest endeavours to disrupt the pharmaceuticals sector — via his Price As well as Drug Enterprise — could possibly compete with Amazon’s most current supplying. In October 2021, Charge Moreover Drug Firm launched a new pharmacy-profit administration companies with a nonprofit alliance of almost 40 large public and non-public companies to handle prescription-drug benefits. Individually, the Mark Cuban Expense Furthermore Drug Organization declared a partnership in January with RxPreferred Rewards concentrated on strengthening healthcare obtain and reducing prescription drug invest.

Some of the difficulties that Amazon will have to contend with heading forward consist of regardless of whether or not the firm wants to develop into extra high-priced drugs for exceptional conditions. Additionally, how it discounts with the drug sector middlemen, referred to as PBMs, and the economics of well being coverage.

“Is it cheaper to use your coverage or not? Occasionally the copay is additional costly than what it would have just been to shell out hard cash. All of that is complicated. And then you could see some of the extra regular players form of combating back again against [Amazon],” pointed out Farr.

Amazon’s new featuring is also yet another way to get Prime customers to expend additional. Amazon initial launched its Key subscription in February 2005 at an preliminary price tag level of $79 a yr, featuring unrestricted two-day shipping and delivery. But right now, the Primary membership program is evolving beyond a mere buying plan or a shipping and delivery system. The organization has far more not long ago been transforming its approach and creating out a set of softer characteristics and positive aspects connected to shaping the media usage routines of its members.

Finally, McCarthy explained this new featuring is far more of a way for Amazon to get its present clients to invest far more with the e-commerce huge. “They do want new buyers, but typically they’re striving to get their loyal buyer base to spend far more with them,” she said.

Posted on

Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon

Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Rite Aid and Amazon

For Immediate Release

Chicago, IL – January 25, 2023 – Today, Zacks Equity Research discusses CVS Health CVS, Walgreens Boots Alliance WBA, Rite Aid RAD and Amazon’s AMZN.

Industry: Pharmacy & Drugstore

Link: https://www.zacks.com/commentary/2043036/3-retail-pharmacy-and-drugstore-stocks-to-watch-amid-industry-headwinds

The past three years of the public health crisis have significantly altered the structure and trend of the Retail – Pharmacies and Drug Stores industry. On a positive note, amid the ongoing supply-chain disruption and staffing shortages within healthcare, the retail pharmacy business has been in high demand, thanks to the exponentially growing demand for distant medical services and remote patient care. Particularly, mail-order pharmacies are registering growth on account of telehealth and remote monitoring services.

Added to this, with digitization, retail industry players are significantly strengthening their omnichannel presence from sole brick-and-mortar dependency. All these are creating unique opportunities for stalwarts within the industry like CVS Health, Walgreens Boots Alliance and Rite Aid, which are investing strategically in easy patient access to prescription and maintenance medications.

However, the majority of the retail drug store heavyweights have been southbound due to the ongoing pressure of drug pricing and reimbursement. Further, with a decline in the severity of COVID-19, the demand for related retail health support has decreased meaningfully, resulting in a significant drop in pandemic-led revenue generation for the industry players.

Last but not least, perceiving the huge growth prospects of this space, there has been a number of new entries in this industry, increasing the competitiveness of the space. Especially, a stalwart like Amazon‘s entry into the retail drugstore space has created a survival issue among the existing entities.

Industry Description

The Zacks Retail – Pharmacies and Drug Stores industry includes retailing of a range of prescription and over-the-counter medications. The broad retail network of companies within the retail pharmacy industry delivers advanced health solutions to patients, customers and caregivers.

Over the past few years, the scope of the retail pharmacy and drugstore market has expanded exponentially. In North America, some of these entities evolved to add wellness products and groceries to their traditional portfolio of prescription and over-the-counter medications. Looking at the attractive growth potentials of this industry,  non-healthcare leaders like Amazon, in 2018, acquired pharmacy delivery startup PillPack to enter the U.S. healthcare space.

3 Trends Shaping the Future of the Retail – Pharmacies and Drug Stores Industry

Industry Trend Remains Dismal Amid Reimbursement Pressure: Brand-name drugs, which hold wide profit margins, are protected with a reliable supply chain. However, the low-margin generic drugs, which have a fragile supply chain network, have been bearing the brunt of the pandemic-induced economic slump. Drug retailers are also witnessing a constant rise in medicine prices, stemming from the rising cost of raw materials of drugs.

The industry players are currently grappling with continued pressure from non-reimbursable pharmacy expenses, which are significantly pulling down the mass demand for prescription as well as over-the-counter drugs and vaccinations. It has been widely observed that patients are replacing prescription medicines with low-cost generic drugs.

Amazon’s Entry Steals Market Share: A Business Insider report in 2021 came up with the speculation that there have been discussions about Amazon setting up standalone stores in a few locations, including Boston and Phoenix. Further, per the report, which cites insider sources, Amazon is exploring plans to place the pharmacies inside Amazon-owned Whole Foods locations. Earlier, following its entry, the e-commerce giant grabbed a significant chunk of the online pharmacy market from the legacy retail drug store space.

Amazon Pharmacy’s omichannel performance has been significantly robust since the inception. Going by a Viseven report of Jan 5, 2023, Amazon’s omnichannel experiences are the keystone to customer retention that help to cover previous sales reductions. This has already significantly increased competition in the retail pharmacy market. Needless to say, the speculation of Amazon planning to enter the Brick-And-Mortar space has come as a major blow to the industry, putting retail pharmacy and drugstore stocks in a tighter spot.

Online Pharmacy and Mail Order Boom: The widespread shelter-in-place regulations since the beginning of the pandemic have created a significant shift in demand toward mail order and online pharmacies. Experts say that this transition is expected to last even after the pandemic is over. Data claims that COVID-19 has only accelerated the already-growing demand for e-pharmacy and mail-ordered home delivery systems.

Going by a Patch report, “Two years ago, 11{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} of U.S. adult pharmacy customers got their prescription from an online pharmacy, based on a survey conducted by market research firm CivicScience, [.] That figure has been steadily rising over the years, according to Statista.com, an online statistics portal.” With Amazon’s big move into the healthcare space, the retail pharmacy industry entered a new phase of fierce competition. To counter this rivalry, the companies are strategically attempting to gain in size and scale.

Zacks Industry Rank Indicates Dull Near-Term Prospects

The industry’s Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates bleak near-term prospects. The Zacks Retail – Pharmacies and Drug Stores industry, housed within the broader Zacks Retail and Wholesale sector, currently carries a Zacks Industry Rank #190, placing it in the bottom 24{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} of more than 250 Zacks industries. Our research shows that the top 50{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} of the Zacks-ranked industries outperforms the bottom 50{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} by a factor of more than 2 to 1.

We will present a few stocks that have the potential to outperform the market based on a strong earnings outlook. But it’s worth taking a look at the industry’s shareholder returns and current valuation first.

Industry Underperforms S&P 500 & Sector

The Zacks Retail – Pharmacies and Drug Stores industry has underperformed the Zacks S&P 500 composite as well as its sector over the past year. The stocks in this industry have collectively lost 20{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} over this period, while the Retail-Wholesale Sector has declined 12.3{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b}. The S&P 500 composite has declined 10{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} over the said time frame.

Industry’s Current Valuation

On the basis of forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 9.3X compared with the S&P 500’s 17.78X and the sector’s 22.14X.

Over the last five years, the sector has traded as high as 12.51X, as low as 7.53X, and at the median of 9.92X.

3 Retail – Pharmacies and Drug Stores Stocks in Focus

CVS Health: CVS Health is currently seeing greater engagement in an expanded set of digital health services such as antibody and PCR testing, vaccinations and omni-channel pharmacy. During the last-reported third quarter of 2022, the company added nearly one million digital customers and is currently serving more than 46 million unique digital customers, an impressive 11 million more since this time last year.

This uptick was driven by the company’s omnichannel pharmacy strategy, focused on simplifying how consumers fill and receive prescriptions. CVS Health’s digital capabilities for health interactions such as COVID testing and vaccines, prescription services, and sales of health and wellness products have dramatically increased consumer engagement across all CVS Health businesses.

The Zacks Consensus Estimate for 2022 revenues indicates a 7.3{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} rise from 2021. CVS Health, a Zacks Rank #3 (Hold) stock, also has an impressive five-year historical earnings growth rate of 8.3{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b}.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Walgreens Boots: Walgreens Boots continues to make progress in transforming the pharmacy business and the method of delivering healthcare, both through physical stores and digital channels. Currently, the company’s U.S. retail business is demonstrating good momentum through digital and omnichannel growth from the myWalgreens loyalty program, owned brand innovation and alternative profit streams.

In the last-reported first quarter of fiscal 2023, the company continued to progress in transforming the pharmacy business and the method of delivering healthcare through physical stores and digital channels. The company is also witnessing mid-single-digit growth in stores with normal hours. Moreover, Walgreens has opened its ninth automated micro fulfillment center, now supporting about 3,000 total stores.

The Zacks Consensus Estimate for fiscal 2023 revenues indicates a rise of 1.5{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} from fiscal 2022. The long-term expected earnings growth rate is pegged at an impressive 5{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b}. Walgreens Boots carries a Zacks Rank #3 at present.

Rite Aid: Rite Aid remains focused on strengthening its foothold in mid-market PBM, innovating across its retail and mail-order pharmacy channels, enhancing the in-store experience by curated digital offerings, improving merchandise and rebranding its image with a new logo. Rite Aid earlier launched the first three Stores of the Future and successfully concluded the acquisition of Bartell, which will help expand its customer base.

The company revealed plans to lower costs via the closure of 145 unprofitable stores, reduced corporate administrative expenses and enhanced efficiencies in worked payroll, and other store labor costs. It also intends to reduce costs related to Elixir due to declining membership.

The Zacks Consensus Estimate for fiscal 2024 earnings indicates a rise of 28.24{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} from fiscal 2023. Rite Aid currently carries a Zacks Rank of #3.

Why Haven’t You Looked at Zacks’ Top Stocks?

Since 2000, our top stock-picking strategies have blown away the S&P’s +6.2 average gain per year. Amazingly, they soared with average gains of +46.4{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b}, +49.5{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} and +55.2{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} per year. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Join us on Facebook: https://www.facebook.com/ZacksInvestmentResearch/

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance  for information about the performance numbers displayed in this press release.

Zacks Names “Single Best Pick to Double”

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} in little more than 9 months and NVIDIA which boomed +175.9{1668a97e7bfe6d80c144078b89af180f360665b4ea188e6054b2f93f7302966b} in one year.

Free: See Our Top Stock and 4 Runners Up >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Rite Aid Corporation (RAD) : Free Stock Analysis Report

Amazon.com, Inc. (AMZN) : Free Stock Analysis Report

CVS Health Corporation (CVS) : Free Stock Analysis Report

Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Posted on

Three Key Lessons for Healthcare and Pharmaceutical Advertisers

Three Key Lessons for Healthcare and Pharmaceutical Advertisers

Healthcare and prescribed drugs is an sector that ordinarily falls powering in adopting the most recent digital marketing developments for several good reasons. On the other hand, with technological advancement and telehealth turning into well-liked, there are key classes for advertisers in the business. Harshit Jain, founder and worldwide CEO, Doceree, discusses the essential learnings for health care advertisers.

The healthcare and pharmaceutical advertising field has historically been guiding in adapting to the most recent trends in digital marketing and advertising. This is because of to numerous things, these as HIPAA and privateness laws which make targeting audiences tough. Not way too extended ago, affected individual health and fitness records and prescription delivery were performed manually. With developments in engineering and the climbing adoption of telehealth, the healthcare and pharmaceutical business is catching up when it arrives to electronic transformation. 

With these progress appear critical learnings for advertisers and entrepreneurs in the healthcare marketplace. As world-wide privateness restrictionsOpens a new window